GlassScriptPhysician profile
Nathan Sneddon
NPI 1427232925
$19,670.11
in general payments reported to CMS, 2019-2025
33 companies · $1,189 in 2025
The $1,189 reported for 2025 was more than what a typical Pain Medicine (Anesthesiology) provider received nationally (typical 2025 total: $458).
See the full distribution for Pain Medicine (Anesthesiology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,078 · 2020: $3,345 · 2021: $1,430 · 2022: $7,410 · 2023: $1,706 · 2024: $3,513 · 2025: $1,189.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,735 · Travel and Lodging: $672.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,735.18 |
| Travel and Lodging | $672.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,420.13 | 2021-2024 | Proclaim, Eterna |
| Relievant Medsystems, INC. | $3,270.92 | 2020-2023 | Intracept |
| Nevro Corp. | $2,958.41 | 2019-2024 | Senza |
| Vertos Medical, INC. | $2,488.48 | 2022-2024 | Mild Device Kit |
| Stimwave Technologies Incorporated | $1,691.80 | 2019-2020 | |
| Boston Scientific Corporation | $1,457.18 | 2019-2025 | Intracept, Intracept Rf Probe, General - Pain Management |
| Mml US, INC. | $1,000.28 | 2024-2025 | Reactiv8 |
| Stryker Corporation | $898.23 | 2021-2025 | Omnicurve, Spinejack |
| Abbvie INC. | $458.54 | 2021-2025 | Ubrelvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $238.91 | 2019-2025 | Relistor |
| Biotronik Nro, INC. | $228.56 | 2025 | Prospera |
| Collegium Pharmaceutical, INC. | $220.31 | 2020-2024 | Belbuca, Xtampza |
| Ipsen Biopharmaceuticals, INC | $207.77 | 2023-2025 | Dysport |
| Alphatec Spine, INC | $168.17 | 2024 | Invictus Mis |
| Medtronic, INC. | $141.40 | 2023 | Kyphon Express II Kyphopak Tray |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $141.12 | 2025 | Evoke |
| Nalu Medical, INC. | $116.24 | 2022-2023 | Nalu Neurostimulation System |
| Pfizer INC. | $101.38 | 2021-2024 | |
| Biodelivery Sciences International, INC. | $99.85 | 2020-2021 | |
| Allergan, INC. | $66.95 | 2019 | |
| Si-Bone, INC. | $56.69 | 2019-2024 | |
| Spr Therapeutics, INC | $52.00 | 2022 | |
| Amgen INC. | $31.19 | 2021 | |
| Fidia Pharma USA INC. | $30.82 | 2019 | |
| Lilly USA, LLC | $26.44 | 2021 | |
| Lundbeck LLC | $17.21 | 2022 | |
| Corcept Therapeutics | $15.67 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.56 | 2020 | |
| Janssen Pharmaceuticals, INC | $14.46 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.59 | 2019 | |
| Medtronic USA, INC. | $12.22 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $11.63 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,114,789.58 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nathan Sneddon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.